A novel binding pocket of cyclin-dependent kinase 2

Related Experiment Video

Updated: Jul 3, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Hao Chen1, Rachel Van Duyne, Naigong Zhang

  • 1Department of Physics, The George Washington University, Washington, District of Columbia 20052, USA.

Proteins
|July 11, 2008
PubMed

Insights

New peptide inhibitors target a noncatalytic site on cyclin-dependent kinase 2 (cdk2), disrupting its complex with cyclin E. This approach offers a novel strategy for developing anticancer therapies by inhibiting cdk2 kinase activity.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Cyclin-dependent kinase 2 (cdk2) is crucial for eukaryotic cell cycle control.
  • Cdk2 is a significant drug target for anticancer therapies.
  • Current inhibitors primarily target the ATP-binding pocket of cdk2.

Purpose of the Study:

  • To investigate novel peptide inhibitors targeting a noncatalytic binding pocket of cdk2.
  • To explore a new therapeutic strategy for inhibiting cdk2 kinase activity.

Main Methods:

  • Identification and characterization of five amino-acid peptide inhibitors.
  • Analysis of peptide binding to a noncatalytic pocket at the cdk2/cyclin interface.
  • In vitro assessment of the impact on cdk2/cyclin E complex stability and kinase activity.

Main Results:

  • Several peptide inhibitors were found to bind to a noncatalytic pocket of cdk2.
  • Binding of these peptides partially disrupted the cdk2/cyclin E complex.
  • The kinase activity of the cdk2/cyclin E complex was diminished in vitro.

Conclusions:

  • A novel noncatalytic binding site on cdk2 can be targeted by peptide inhibitors.
  • Targeting this site offers a new avenue for developing cdk2-based anticancer drugs.
  • Partial disruption of the cdk2/cyclin E complex can reduce kinase activity.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Related Concept Videos

Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...